Recursion Pharmaceuticals Inc

Common Name
Recursion Pharmaceuticals
Country
United States
Sector
Healthcare
Industry
Biotechnology
Employees
800
Ticker
RXRX
Exchange
NASDAQ/NGS
Description
Recursion Pharmaceuticals Inc. is a biotechnology company focused on utilizing machine learning and artificial intelligence to accelerate drug discovery and development. By integrating cutting-edge co...

Recursion Pharmaceuticals's GHG Emissions Data Preview

In 2023, Recursion Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), and Scope 2 (indirect emissions from purchased energy).

However, Recursion Pharmaceuticals has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.

Metric (tCO2e)2024202320222021 - 2017
Total Scope 1
0000000
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
0000000
Total Scope 2
Market-Based
0000000
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
0000000
Location-Based
0000000
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
0000000
Total Scope 3
0000000
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
0000000

This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.

Insights into Recursion Pharmaceuticals's Operational Emissions

In 2023, the total operational greenhouse gas (GHG) emissions of Recursion Pharmaceuticals amounted to 2,718 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).

Compared to 2022, the total operational greenhouse gas (GHG) emissions of Recursion Pharmaceuticals increased by 117.61%, suggesting that the company faced challenges in reducing its emissions from its core operations.

Recursion Pharmaceuticals's Scope 1 Emissions Over Time

2022202302505007501 ktCO2e+217%
  • Total Scope 1
  • Year-over-Year Change

What are Recursion Pharmaceuticals's Scope 1 emissions?

In 2023, the total Scope 1 emissions of Recursion Pharmaceuticals were 854 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).

Compared to the previous year (2022), Recursion Pharmaceuticals's Scope 1 emissions increased by 217.47%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.

What are Recursion Pharmaceuticals's Scope 2 emissions?

In 2023, Recursion Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 1,474 tCOâ‚‚e using the market-based method, and 1,864 tCOâ‚‚e using the location-based method.

What methodology does Recursion Pharmaceuticals use for Scope 2 reporting?

In 2023, Recursion Pharmaceuticals reported its Scope 2 emissions using the market-based method and using the location-based method.

Recursion Pharmaceuticals's Scope 2 Emissions Over Time

2022202305001 k1.5 k2 ktCO2e
  • Total Scope 2 Location-Based
  • Total Scope 2 Market-Based
Want Full Access to Recursion Pharmaceuticals's GHG Emissions Dataset?
Sign Up